Spero Therapeutics CEO Ankit Mahadevia's 2022 pay slips 13% to $4.2M
Spero Therapeutics reports 2022 executive compensation
By ExecPay News
Published: September 1, 2023
Spero Therapeutics reported fiscal year 2022 executive compensation information on September 1, 2023.
In 2022, three executives at Spero Therapeutics received on average a compensation package of $2.5M, a 1% increase compared to previous year.
Average pay of disclosed executives at Spero Therapeutics
Ankit Mahadevia, Chief Executive Officer, received $4.2M in total, which decreased by 13% compared to 2021. 35% of Mahadevia's compensation, or $1.5M, was in stock awards. Mahadevia also received $254K in bonus, $343K in non-equity incentive plan, $1.5M in option awards, $634K in salary, as well as $9.7K in other compensation.
Satyavrat Shukla, Chief Executive Officer, received a compensation package of $1.7M, which decreased by 25% compared to previous year. 29% of the compensation package, or $478K, was in salary.
Tamara Joseph, Chief Legal Officer, earned $1.6M in 2022, a 66% increase compared to previous year.
Related executives
You may also like
Source: SEC filing on September 1, 2023.